GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Read more
European Commission (EC) Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) Read more
GSK’s Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps Read more
LPOXY Therapeutics, Inc. Acquires Key Assets from Xeno Biosciences Inc. to Advance C. difficile Prevention Therapy Read more
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study Read more
China’s NMPA Approves VYLOY (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Read more
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Bloodstream Infections Read more
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer Read more